{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=8", "query": { "intervention": "Combination Treatment - Cohort 3", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1069, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment+-+Cohort+3&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:04:19.071Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05091424", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-03-07", "completion_date": "2032-02-10", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 5, "location_summary": "Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091424" }, { "nct_id": "NCT07470853", "title": "A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PROC", "Platinum Resistant Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "HWK-016, MUCIN-16-targeted ADC", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Whitehawk Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2026-03-15", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07470853" }, { "nct_id": "NCT03873883", "title": "First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "EOS100850", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2019-02-05", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 3, "location_summary": "Michigan Center, Michigan • Hackensack, New Jersey • San Antonio, Texas", "locations": [ { "city": "Michigan Center", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03873883" }, { "nct_id": "NCT00268905", "title": "A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "E7389 + carboplatin AUC 5", "type": "DRUG" }, { "name": "E7389+carboplatin AUC 6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2006-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268905" }, { "nct_id": "NCT06109272", "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-01-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109272" }, { "nct_id": "NCT00086983", "title": "Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "becatecarin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086983" }, { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" }, { "nct_id": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pharmacokinetics of Zolbetuximab", "Gastric Cancer", "Gastro-esophageal Junction (GEJ) Cancer", "Pharmacokinetics of Oxaliplatin", "Pharmacokinetics of Fluorouracil Bolus (5-FU)" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-06-29", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 6, "location_summary": "Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505320" }, { "nct_id": "NCT03222609", "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2017-10-31", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222609" }, { "nct_id": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Cusatuzumab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoVerity, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-12-23", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-12T23:04:19.071Z", "location_count": 11, "location_summary": "Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150887" } ] }